2017 Annual Meeting

SC30-Diagnosis of Renal Neoplasms Using Integrated Histologic, Cytologic and Molecular Approaches in the Era of Precision Medicine

March 9 2017, 1:00pm to 4:30pm

Description

SC30-Diagnosis of Renal Neoplasms Using Integrated Histologic, Cytologic and Molecular Approaches in the Era of Precision Medicine

 

Session Credits: 3 CME and 3 SAMs

 

Faculty: Christopher Przybycin, MD and Jordan Reynolds, MD, Cleveland Clinic, Cleveland, OH and Ming Zhou, MD, PhD, University of Texas Southwestern Medical Center, Dallas, TX

Diagnosis and classification of renal tumors have undergone tremendous changes in the last decade. Many new entities have been discovered. The molecular mechanisms of many tumors have been unraveled and consequently many new biomarkers and molecular tests have been increasingly used in the diagnosis and prognotification of renal tumors. Targeted therapy is available for many specific subtypes of renal tumors. All these changes will be included in the new World Health Organization Classification of Renal Neoplasia, which will be published in early 2016. It is imperative for practicing pathologists to keep abreast with the "new" tumor entities, diagnostic criteria, diagnostic markers and tests, and recent changes to the grading and staging criteria for renal cell carcinomas. Rather than a rote list of tumors with characteristics, this practically oriented course will use cases that speakers collected from their daily signout to provide a pattern-based diagnostic approach that incorporates both "old" diagnostic entities and newly described entities that are important to recognize. When applicable, we will also provide ancillary testing methods including immunohistochemistry and molecular testing important for the work-up of renal tumors. This course is designed for advanced residents, fellows and general pathologists, as well as subspecialists in urological pathology.

Upon completion of this educational activity, participants should be able to:

  1. Recognize newly described renal tumor entities in renal neoplasia
  2. Understand the molecular genetics of renal tumors that is most relevant to their clinical practice
  3. Use pattern-based approach to the diagnosis of renal tumors, including new and old entities
  4. Use immunohistochemistry in the work-up of difficult renal tumors
  5. Be aware of important changes to the reporting RCC, including grading and staging,
  6. Understand the approach to work-up of needle biopsy of renal tumors.

Meetings

home-circle-inset-1
view more